Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

about

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

Item

http://www.wikidata.org/entity/Q57823773

description

scientific article published on 18 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Measurement of coagulation fac ...... ults from two crossover trials

@en

Measurement of coagulation fac ...... ults from two crossover trials

@nl

type

Item

label

Measurement of coagulation fac ...... ults from two crossover trials

@en

Measurement of coagulation fac ...... ults from two crossover trials

@nl

prefLabel

Measurement of coagulation fac ...... ults from two crossover trials

@en

Measurement of coagulation fac ...... ults from two crossover trials

@nl

P1476

Measurement of coagulation fac ...... ults from two crossover trials

@en

P2093

Michiel Coppens

http://www.w3.org/2001/XMLSchema#string

Saskia Middeldorp

http://www.w3.org/2001/XMLSchema#string

Willem M Lijfering

http://www.w3.org/2001/XMLSchema#string

Yuk W Cheung

http://www.w3.org/2001/XMLSchema#string

P2860

Deep vein thrombosis and pulmonary embolism.

Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE.

Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy.

Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study.

D-dimer at venous thrombosis diagnosis is associated with risk of recurrence.

In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.

In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.

Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study.

P304

689-695

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/RTH2.12142

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

S Barco

Suzanne C. Cannegieter

Luuk J J Scheres

P577

2018-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30349888

http://www.w3.org/2001/XMLSchema#string

P932

6178718

http://www.w3.org/2001/XMLSchema#string